• Explore /
  • Poster
  • / A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

Abstract Poster

Authors

null

Chee Khoon Lee

St George Hospital, Kogarah, Australia

Chee Khoon Lee , Shalini Subramaniam , Antony Mersiades , Jenna Mitchell , Hannora Jurkovic , Mariya Walker , Loc Le , Chris Brown , Benjamin J. Solomon , Tom John , Martin R. Stockler , Bin-Chi Liao , James Chih-Hsin Yang , Chao-Hua Chiu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03994393

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS9631)

DOI

10.1200/JCO.2020.38.15_suppl.TPS9631

Abstract #

TPS9631

Poster Bd #

397

Abstract Disclosures

Similar Posters

First Author: Michal Sarfaty

First Author: Satoshi Oizumi

First Author: Shintaro Kanda

First Author: Helena Alexandra Yu